The antibiotic, which was recently approved for treatment of urinary tract infections, was found to be noninferior to the standard gonorrhea treatment.
A study of 40 female sex workers reveals that a single daily dose of doxycycline is associated with significantly reduced STIs, primarily syphilis.
The at-home test can detect chlamydia, gonorrhea, and trichomoniasis and deliver results within 30 minutes.
Researchers found that roughly 30% of chlamydia and gonorrhea patients did not receive treatment, while only 14% and 39% received recommended antibiotics.
Researchers found "exceedingly high" levels of gonococcal tetracycline resistance in 8 African and Asian countries.
Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
Among patients prescribed doxycycline post-exposure prophylaxis, cases of syphilis, chlamydia, and gonorrhea fell by 86.4%. 89.7%, and 54.7%, respectively.
The rate of gonorrhea cases across Europe rose by 31% in 2023 compared with 2022, and is up 321% since 2014.
Two studies in California found significant reductions in chlamydia and syphilis in the year after doxycycline post-exposure prophylaxis guidelines were released.
The partnership will evaluate the clinical need and address market barriers for diagnostic, therapeutic, and preventive interventions for gonorrhea in low-resource countries.
